Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Summary not available.
Abbott (NYSE: ABT) and the Big Ten Conference are relaunching the nationwide “We Give Blood” competition as the U.S. faces a national blood crisis, following a four-year summer low in donations reported by the American Red Cross. All 18 Big Ten universities will compete to generate the most blood donations, with Abbott awarding $1 million to the winning school to support student or community health initiatives.
The 2026 campaign accepts donations made anywhere in the U.S. from Aug. 12 to Dec. 4, with official competition tracking starting Aug. 26 via BigTen.org/Abbott or by texting GIVEBLOOD to 222688. Donors can receive a limited-edition, school-specific T-shirt while supplies last. The initiative targets younger donors to address long-term supply sustainability, building on prior years in which more than 100,000 donations were logged and nearly one-third of student donors gave blood for the first time.
Abbott (NYSE: ABT) announced a multi-year partnership with Google Health on Aug. 11, 2026 to link ongoing glucose insights from Abbott’s over-the-counter Lingo continuous glucose monitor with Google’s AI and consumer technology. The collaboration aims to make personalized metabolic insights more actionable for adults not using insulin.
Through the Google Health app, Lingo users will be able to see glucose trends alongside other health and wellness metrics and receive AI-powered guidance from Google Health Coach on nutrition, activity, sleep and recovery. The partnership also includes one of the largest real-world metabolic health studies to integrate continuous glucose, wearable, lab and survey data, which is intended to inform future AI coaching in Google Health and new Lingo features. Lingo integrations in Google Health are expected to roll out later this year, with Google Health Coach available via a Google Health Premium subscription on select devices.
Abbott (NYSE: ABT) reported second-quarter 2026 sales of $12.6 billion, up 13.0% on a reported basis and 4.8% on a comparable basis. GAAP diluted EPS was $0.53 and adjusted diluted EPS was $1.31, excluding specified items. According to Abbott, the company reaffirmed full-year 2026 comparable sales growth guidance of 6.5%–7.5% and raised full-year adjusted EPS guidance to $5.45–$5.60 from $5.38–$5.58, and guided third-quarter adjusted EPS to $1.38–$1.46.
Diagnostics sales rose 42.3% reported (2.9% comparable), Medical Devices grew 9.0% reported (8.4% comparable), Established Pharmaceuticals grew 8.4% reported (8.7% comparable), while Nutrition declined 3.1% reported (3.6% comparable). Abbott returned $2.1 billion to shareholders via dividends and buybacks and declared its 410th consecutive quarterly dividend. The quarter also included completion of enrollment in the TECTONIC pivotal trial, CE Mark for Libre Duo, FDA submission for Amulet 360, and new data supporting pulsed field ablation and conduction system pacing portfolios.
Abbott (NYSE:ABT) plans to release its second-quarter 2026 earnings on Thursday, July 16, 2026, before the market opens.
The earnings release will be followed by a live webcast conference call at 8 a.m. CT (9 a.m. ET), available via Abbott's investor relations website.
ALZpath announced a global licensing agreement with Abbott (NYSE: ABT) to use ALZpath’s proprietary pTau217 antibody in developing an in vitro diagnostic blood test for Alzheimer’s disease on Abbott’s Alinity ci-series systems.
The antibody is supported by 200+ publications across 18 countries and aims to offer a scalable blood-based alternative to PET imaging and cerebrospinal fluid analysis for earlier Alzheimer’s detection and potential disease monitoring.
Similac (NYSE:ABT) released survey findings on how social media affects young parents and launched its “Love Without Measure” initiative. A national online survey of 1,002 U.S. adults aged 22-32 found 93% expect parenthood to be fulfilling, yet nearly 80% feel pressure to be “perfect” on social media.
The initiative encourages parents to share unfiltered stories using #LoveWithoutMeasure, partners with motherhood experts and influencers, and promotes realistic, judgment-free parenting content across Instagram, Facebook, TikTok and Similac.com.
Abbott (NYSE: ABT) declared a quarterly common dividend of $0.63 per share, its 410th consecutive quarterly dividend since 1924. The cash dividend is payable August 17, 2026 to shareholders of record on July 15, 2026.
Abbott has raised its dividend for 54 straight years and is part of the S&P 500 Dividend Aristocrats Index.
Abbott (NYSE:ABT) reported new research from its Healthy Food Rx “Food is Medicine” program, paired with community health worker coaching, in 284 adults with type 2 diabetes over six months.
Participants showed higher fruit, vegetable and water intake, more physical activity, better self-management, improved self-reported health and reduced food insecurity.
Abbott (NYSE:ABT) released new data showing diabetic ketoacidosis (DKA) is rising across age groups and can be difficult to recognize early, especially at hospital admission. Studies cited report about a 24% rise in DKA hospitalizations for Type 1 diabetes between 2017-2024 and nearly 60% of pediatric diabetes hospitalizations driven by DKA.
Abbott highlights gaps in ketone awareness and testing and notes that most continuous glucose monitors do not measure ketones. The company has developed dual glucose-ketone sensors, Libre Duo and Libre Duo 10 Day, which obtained CE Mark in May 2026 and are pending FDA clearance.